BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose...

Related Keywords

United States ,Irvine ,California ,Toronto ,Ontario ,Canada ,Cambridge ,Cambridgeshire ,United Kingdom ,Berlin ,Germany ,Copenhagen ,Køavn ,Denmark ,Bluerock ,Harini Sarva ,Alfonso Fasano ,Christian Rommel ,Alan Susan Hudson ,Claire Henchcliffe ,Ahmed Enayetallah ,Viviane Tabar ,Andres Lozano ,Twitter ,University Health Network ,University Of Toronto Uo ,Linkedin ,Cancer Center ,International Congress ,Department Of Neurosurgery At Memorial Sloan Kettering ,Movement Disorders ,Krembil Brain Institute ,Head Of Development ,Parkinson Foundation ,Bayer Ag ,Facebook ,Head Of Research ,University Of California ,School Of Medicine Department Neurology ,Division Of Neurosurgery ,Bluerock Therapeutics ,Unified Parkinson ,Disease Rating Scale Part ,Hauser Diary ,Medicine Department ,Senior Vice President ,Executive Committee ,Pharmaceuticals Division ,Memorial Sloan Kettering ,Senior Scientist ,Susan Hudson Cornerstone Chair ,Toronto Western Hospital ,Weill Cornell Medicine ,Multi Disciplinary Care ,Sloan Kettering ,Health Network ,Versant Ventures ,Gene Therapy ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,Surveys ,Olls And Research ,